Health care expenditures among long-term survivors of pediatric solid tumors: Results from the French Childhood Cancer Survivor Study (FCCSS) and the French network of cancer registries (FRANCIM).
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
26
05
2021
accepted:
06
04
2022
entrez:
26
5
2022
pubmed:
27
5
2022
medline:
31
5
2022
Statut:
epublish
Résumé
Childhood cancer survivors (CCS) may require lifelong medical care due to late effects of cancer treatments. Little is known about of their healthcare utilization and expenditures at long-term especially in publicly funded health care system. We aim to estimate and describe the health care expenditures among long-term CCS in France. A total of 5319 five-year solid CCS diagnosed before the age of 21 between 1945 and 2000 in France were identified in the French Childhood Cancer Survivors Study cohort (FCCSS) and the French cancer registry. Information about health care expenditure was taken from the French national health data system between 2011 and 2016, and was described according to survivors' characteristics. Generalized linear models were used to determine associations between health care expenditures and survivors' characteristics. Mean annual amount of healthcare expenditures was € 4,255. Expenditures on hospitalizations and pharmacy represents 60% of total expenditures. Mean annual of healthcare expenditures were higher at increasing age, among women survivors (€ 4,795 vs € 3,814 in men) and in central nervous system (CNS) tumor survivors (€ 7,116 vs € 3,366 in lymphoma and € 3,363 in other solid tumor survivors). Childhood cancer survivorship is associated with a substantial economic burden in France. We found that female gender and CNS primary cancer were associated with increased healthcare expenditures.
Sections du résumé
BACKGROUND
Childhood cancer survivors (CCS) may require lifelong medical care due to late effects of cancer treatments. Little is known about of their healthcare utilization and expenditures at long-term especially in publicly funded health care system. We aim to estimate and describe the health care expenditures among long-term CCS in France.
METHODS
A total of 5319 five-year solid CCS diagnosed before the age of 21 between 1945 and 2000 in France were identified in the French Childhood Cancer Survivors Study cohort (FCCSS) and the French cancer registry. Information about health care expenditure was taken from the French national health data system between 2011 and 2016, and was described according to survivors' characteristics. Generalized linear models were used to determine associations between health care expenditures and survivors' characteristics.
RESULTS
Mean annual amount of healthcare expenditures was € 4,255. Expenditures on hospitalizations and pharmacy represents 60% of total expenditures. Mean annual of healthcare expenditures were higher at increasing age, among women survivors (€ 4,795 vs € 3,814 in men) and in central nervous system (CNS) tumor survivors (€ 7,116 vs € 3,366 in lymphoma and € 3,363 in other solid tumor survivors).
CONCLUSIONS
Childhood cancer survivorship is associated with a substantial economic burden in France. We found that female gender and CNS primary cancer were associated with increased healthcare expenditures.
Identifiants
pubmed: 35617253
doi: 10.1371/journal.pone.0267317
pii: PONE-D-21-17399
pmc: PMC9135272
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0267317Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Clin Oncol. 2018 Jul 20;36(21):2169-2180
pubmed: 29874135
Int J Cancer. 2017 Jun 15;140(12):2678-2692
pubmed: 28316069
BMC Public Health. 2009 Jan 22;9:33
pubmed: 19161613
Pharmacoepidemiol Drug Saf. 2017 Aug;26(8):954-962
pubmed: 28544284
PLoS One. 2020 May 19;15(5):e0232708
pubmed: 32427994
J Clin Oncol. 2007 Nov 20;25(33):5262-6
pubmed: 18024873
J Clin Oncol. 2010 Nov 10;28(32):4810-8
pubmed: 20351333
J Adolesc Young Adult Oncol. 2017 Dec;6(4):524-534
pubmed: 28541785
BMC Cancer. 2020 Mar 6;20(1):190
pubmed: 32138705
Rev Epidemiol Sante Publique. 2017 Oct;65 Suppl 4:S149-S167
pubmed: 28756037
Rev Epidemiol Sante Publique. 2016 Jun;64(3):175-83
pubmed: 27238162
J Clin Oncol. 2018 Jul 20;36(21):2198-2205
pubmed: 29874136
Cancer. 2016 Dec 15;122(24):3873-3882
pubmed: 27518040
Lancet. 2017 Dec 9;390(10112):2569-2582
pubmed: 28890157
J Clin Oncol. 2018 Jul 20;36(21):2216-2222
pubmed: 29874139
C R Acad Sci III. 1995 Apr;318(4):483-90
pubmed: 7648361
Cancer Med. 2019 Nov;8(15):6671-6683
pubmed: 31553130
J Natl Cancer Inst. 2019 Feb 1;111(2):189-200
pubmed: 30085213
Cancer Causes Control. 2018 Nov;29(11):1047-1057
pubmed: 30187228
Circulation. 2016 Jan 5;133(1):31-8
pubmed: 26487757
Pediatr Blood Cancer. 2012 Jul 15;59(1):126-32
pubmed: 22180128
N Engl J Med. 2006 Oct 12;355(15):1572-82
pubmed: 17035650
Eur J Cancer. 2015 Jul;51(10):1203-11
pubmed: 25958037
BMJ. 2016 Sep 01;354:i4351
pubmed: 27586237
Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1280-9
pubmed: 24925676
Br J Cancer. 2016 Apr 26;114(9):1060-8
pubmed: 27115571
Eur J Cancer. 2007 Jan;43(1):149-60
pubmed: 17084622
Pediatrics. 2016 Nov;138(Suppl 1):S15-S21
pubmed: 27940973
Arch Dis Child. 2020 Apr;105(4):339-346
pubmed: 31601570
Pediatr Blood Cancer. 2021 Jul;68(7):e28941
pubmed: 33565257
Pediatr Blood Cancer. 2006 Feb;46(2):159-68
pubmed: 16369920
Health Aff (Millwood). 2014 Jun;33(6):1024-31
pubmed: 24889952
Int J Cancer. 2019 Apr 15;144(8):1796-1823
pubmed: 30098012
Bull Cancer. 2020 Mar;107(3):308-321
pubmed: 32035648
Int J Radiat Oncol Biol Phys. 1995 Feb 1;31(3):445-51
pubmed: 7852105
J Clin Oncol. 2017 Oct 20;35(30):3474-3481
pubmed: 28817372
PLoS One. 2018 Oct 31;13(10):e0206448
pubmed: 30379946
Int J Qual Health Care. 2011 Jun;23(3):331-41
pubmed: 21504959